IP Library Granted Patent US 11,304,998
Granted Patent B2
US 11,304,998 · App. 17/240,285 · Granted Apr 19, 2022

Combination immunotherapies comprising IL-15 superagonists

Inventors: Frank R. Jones (Seattle, WA); Adrian Rice (Seattle, WA); Elizabeth Gabitzsch (Seattle, WA); Yvette Latchman (Seattle, WA); Joseph Balint (Seattle, WA)
Assignee: Etubics Corporation
A61K39/001182A61K39/39A61P35/00C12N15/86A61K2039/5256A61K2039/53A61K2039/55527
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,304,998
App. No.
17/240,285
Granted
Apr 19, 2022
Kind
B2
Abstract

Methods and compositions for generating enhanced immune responses using adenovirus vectors that allow for multiple vaccinations in combination with an IL-15 superagonist complex in subjects in need thereof are provided.

Claims (11)

1. A composition comprising a first recombinant adenovirus subtype 5 (Ad5) vector comprising a deletion in an E1 gene region, a deletion in an E2b gene region, and a nucleic acid sequence encoding a carcinoembryonic antigen (CEA) according to SEQ ID NO:3 or SEQ ID NO:4, and:

a) a second recombinant adenovirus vector comprising a nucleic acid sequence encoding an IL-15N72D domain of a human interleukin-15 (IL-15) superagonist complex and an IL-15RaSu/Fc fusion domain of the IL-15 superagonist complex; or

b) a third recombinant adenovirus vector comprising a nucleic acid sequence encoding an IL-15N72D domain of a human IL-15 superagonist complex and fourth recombinant adenovirus vector comprising a nucleic acid sequence encoding an IL-15RαSu/Fc fusion domain of the IL-15 superagonist complex.

2. The composition of claim 1 , wherein the CEA is SEQ ID NO: 3.

3. The composition of claim 1 , wherein the nucleic acid sequence encoding CEA is SEQ ID NO: 1 or SEQ ID NO: 100.

4. The composition of claim 1 , wherein the CEA is SEQ ID NO:4.

5. The composition of claim 1 , wherein the IL-15 superagonist complex is ALT-803.

6. The composition of claim 1 , wherein the composition comprises at least 1×10 9 viral particles in a single dose.

7. The composition of claim 6 , wherein the composition comprises 1×10 9 -5×10 12 viral particles in a single dose.

8. The composition of claim 7 , wherein the composition comprises 1×10 10 -5×10 12 viral particles in a single dose.

9. The composition of claim 8 , wherein the composition-comprises 1×10 10 -5×10 11 viral particles in a single dose.

Assignments (2)
SECURITY INTEREST Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2021
From: JONES, FRANK R.; RICE, ADRIAN; GABITZSCH, ELIZABETH; LATCHMAN, YVETTE; BALINT, JOSEPH
To: ETUBICS CORPORATION
Reel/Frame 056329/0084 →
Continuity (3)
Continuation 16614909
Provisional Application 62511845 · May 26, 2017
Related Publication 20210260175A1 · Aug 26, 2021
Cited By (1)
US 12,370,250